Lepu Medical's half-year profit fell significant business adjustment.

Pharmaceutical Network August 3, the evening of July 29, Lepu Medical announced that the company intends to its controlling subsidiary Beijing Lepu DiagnosticTechnology Co., Ltd. (hereinafter referred to as "Lepu Diagnostics") to split into the company board listing, the completion of the separation will not affect the control of subsidiary Lepu Diagnostics.
Lepu's main business is the development, production and sales of in vitro diagnostic reagents and instruments.
Lepu Medical said that the current company's in vitro diagnostic business scale is relatively low, after the spin-off listing, in vitro diagnostics sector has become an independent listed business sector, its business positioning is more clear.
enhances the profitability of Lepu Diagnostics by expanding the financing channels, enhancing the financial strength, and enhancing the research and development capabilities and the competitiveness of the industry by listing on the company's board.
in the time of listing, Lepu Diagnostics will be approved by the Shanghai Stock Exchange and the China Securities Regulatory Commission after registration to choose the appropriate time for the issue, the issue involves strategic placement, fund raising purposes, underwriting methods, over-allotment options (if applicable), will be based on the implementation of the listing plan, market conditions, policy adjustments and the views of regulatory agencies for further confirmation and adjustment.
half-year profit fell on July 6, Lepu issued a half-year results forecast, the first half of 2020 is expected to return to the mother's net profit of about 1.04 billion yuan - 1.271 billion yuan, down about 10% year-on-year.
explained in its announcement that the overall performance of implants and medical services was significantly lower during the reporting period, when the overall performance of implants and medical services declined from the same period, affected by the outbreak of new coronary pneumonia.
entered the second quarter with the improvement of the domestic outbreak of new coronapneumonia, implantation equipment and medical services have shown a good growth trend. exports of
new crown outbreak-related products also contributed to the corresponding performance, equipment-related marketing revenue increased by more than 60% in the second quarter compared with the same period last year;
second-quarter profit increased 35%-70% year-on-year.
the comprehensive first and second quarter operations, the first half of the main business attributable to shareholders of listed companies is expected to be 15%-35% of the year-on-year growth in non-net profit.
the reporting period, the non-recurring profit and loss is expected to affect the company's net profit attributable to shareholders of listed companies by about 20 million yuan, mainly due to the shanghai Junshi Biopharmaceutical Technology Co., Ltd. related income of 235.8108 million yuan.
the contribution of net profit and non-recurring profit and loss from the main business of the above-mentioned companies, the net profit range attributable to shareholders of listed companies is expected to be RMB 103,983.90 million to RMB127,091.44 million, a fluctuation of -10%-10% over the same period last year.
official response to the inquiry Lepu Medical 2019 revenue, return to the mother net profit, non-return net profit of 7.796 billion, 1.725 billion, 1.241 billion, up 22.64 percent, 41.57 percent, 18.21 percent, overall performance stable growth.
, Lepu (Beijing) Medical Devices Co., Ltd. responded to a letter of inquiry regarding the 2019 annual report, which covers the medical device section.
Question: Please indicate whether your company and other surviving entities controlled or invested by your company and Lepu Bio remain independent in personnel, business, products, finance, procurement and sales channels, customers, suppliers, etc., and whether there is a situation in which you operate the same or similar business.
Lepu replied that the company has now established a medical device, medicine, medical services and new medical industry four sectors of the cardiovascular health industry chain.
in the medical device, the company's main products cover stent systems, blockers, pacemakers and surgical equipment high-value consumables and other sub-sectors.
, the company and Lepu Bio are involved in the pharmaceutical sector, but the business is completely different, the differences are as follows: the company's pharmaceutical sector business is mainly related to the cardiovascular field of pharmaceutical, the main end-customer groups for cardiovascular patients.
Lepu Bio's main business area is antibody, protein, tumor immunity-related biopharmaceuticals in the field of cancer, the main customer group is tumor patients.
, therefore, the company and Lepu Bio do not operate the same or similar business circumstances.
.